The pharmacological blockade of these transporters (e.g., GPNA, V-9302) or inhibition of glutaminase (GLS), a key enzyme in glutamine catabolism (e.g., CB-839), has demonstrated anti-tumor efficacy in lymphoma models [47,91]. The gene discussed is GLS; the disease is neoplasm.